Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015

Human Gene Therapy

Volumn 26, Issue 5, 2015, Pages 276-285

  Gilham, David Edward ^a   Anderson, John ^b   Bridgeman, John Stephen ^c   Hawkins, Robert Edward ^a,c   Exley, Mark Adrian ^d   Stauss, Hans ^e   Maher, John ^f   Pule, Martin ^g   Sewell, Andrew Kelvin ^h   Bendle, Gavin ⁱ   Lee, Steven ⁱ   Qasim, Waseem ^b   Thrasher, Adrian ^b   Morris, Emma ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Cellular Therapeutics Ltd   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL THERAPY; CLINICAL TRIAL (TOPIC); HEALTH CARE DELIVERY; HUMAN; NATIONAL HEALTH SERVICE; NONHODGKIN LYMPHOMA; REGULATORY T LYMPHOCYTE; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UNITED KINGDOM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; BIOLOGICAL THERAPY; BIOTECHNOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASMS; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; BIOTECHNOLOGY; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES; UNITED KINGDOM;

EID: 84929721757     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.024     Document Type: Review

References (67)

1. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011;11:473-487.
2. Moosmann A, Hammerschmidt W, Kolb HJ. Virus-specific T cells for therapy - approaches, problems, solutions. Eur J Cell Biol 2012;91:97-101.
3. Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-4800.
4. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-4557.
5. Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog 2014;19:133-141.
6. Exley MA, Lynch L, Varghese B, et al. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol 2011;140:184-195.
7. Fujii S, Shimizu K, Okamoto Y, et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol 2013; 4:409.
8. Mussai F, De Santo C, Cerundolo V. Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. J Immunother 2012;35:449-459.
9. Karadimitris A, Chaidos A. The role of invariant NKT cells in allogeneic hematopoietic stem cell transplantation. Crit Rev Immunol 2012;32:157-171.
10. Heczey A, Liu D, Tian G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 2014;124: 2824-2833.
11. Wada I, Matsushita H, Noji S, et al. Intraperitoneal injection of in vitro expanded vgamma9vdelta2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 2014;3:362-375.
12. Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013;20:1029-1032.
13. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
14. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: long term follow up and correlates with response. Clin Cancer Res 2015;21:1019-1027.
15. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-924.
16. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra225.
17. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
18. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122:4129-4139.
19. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cyto-kine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-2720.
20. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-549.
21. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-528.
22. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-1517.
23. Gilham DE, Debets R, Pule M, et al. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 2012;18:377-384.
24. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014;2:112-120.
25. Thistlethwaite FC, Elkord E, Griffiths RW, et al. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2008; 57:623-634.
26. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.
27. Hunig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012;12: 317-318.
28. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785-793.
29. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002;5:788-797.
30. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153.
31. Westwood JA, Murray WK, Trivett M, et al. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther 2008;15:1056-1066.
32. Kershaw MH, Westwood JA, Slaney CY, et al. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology 2014;3:e16.
33. Guest RD, Kirillova N, Mowbray S, et al. Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother 2014;63:133-145.
34. Xue SA, Gao L, Ahmadi M, et al. Human MHC class I-restricted high avidity CD4 + T cells generated by cotransfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2013;2:e22590.
35. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062-3067.
36. Xue SA, Gao L, Thomas S, et al. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 2010; 95:126-134.
37. Davies DM, Foster J, Van Der Stegen SJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med 2012;18:565-576.
38. Wilkie S, Burbridge SE, Chiapero-Stanke L, et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 2010;285:25538-25544.
39. Van Schalkwyk MC, Papa SE, Jeannon JP, et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 2013;24:134-142.
40. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-851.
41. Morris EC, Tsallios A, Bendle GM, et al. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci USA 2005;102:7934-7939.
42. Perro M, Tsang J, Xue SA, et al. Generation of multifunctional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther 2010;17:721-732.
43. Thomas S, Xue SA, Bangham CR, et al. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 2011;118:319-329.
44. Thomas S, Xue SA, Cesco-Gaspere M, et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol 2007;179:5803-5810.
45. Field AC, Vink C, Gabriel R, et al. Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer. PLoS One 2013;8:e68201.
46. Qasim W, Brunetto M, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-491.
47. Chen Y, Ayaru L, Mathew S, et al. Expansion of antimesothelin specific CD4 + and CD8 + T cell responses in patients with pancreatic carcinoma. PLoS One 2014;9: e88133.
48. Pospori C, Xue SA, Holler A, et al. Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood 2011;117:6813-6824.
49. Wright GP, Notley CA, Xue SA, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA 2009;106:19078-19083.
50. Linnemann C, Heemskerk B, Kvistborg P, et al. Highthroughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 2013;19:1534-1541.
51. Bendle GM, Linnemann C, Bies L, et al. Blockade of TGFbeta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 2013;191:3232-3239.
52. Frumento G, Zheng Y, Aubert G, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant 2013;13:45-55.
53. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005;23:349-354.
54. Cole DK, Miles KM, Madura F, et al. T-cell receptor (TCR) peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem 2014;289:628-638.
55. Madura F, Rizkallah PJ, Miles KM, et al. T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem 2013;288:18766-18775.
56. Oates J, Hassan NJ, Jakobsen BK. ImmTacs for targeted cancer therapy: why, what, how, and which. Mol Immunol 2015; [Epub ahead of print] DOI: 10.1016/j.molimm .2015.01.024
57. Oates J, Jakobsen BK. ImmTACs: novel bi-specific agents for targeted cancer therapy. Oncoimmunology 2013;2:e22891.
58. Liddy N, Bossi G, Adams KJ, et al. Monoclonal TCRredirected tumor cell killing. Nat Med 2012;18:980-987.
59. Tan MP, Gerry AB, Brewer JE, et al. TCR binding affinity governs the functional profile of cancer-specific CD8 T cells. Clin Exp Immunol 2014;180:255-270.
60. Cole DK, Pumphrey NJ, Boulter JM, et al. Human TCRbinding affinity is governed by MHC class restriction. J Immunol 2007;178:5727-5734.
61. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008;14:1390-1395.
62. Cheadle EJ, Sheard V, Rothwell DG, et al. Differential role of TH1 and TH2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol 2014;192:3654-3665.
63. Alcantar-Orozco EM, Gornall H, Baldan V, et al. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods 2013;24:310-320.
64. Zhan H, Gilmour K, Chan L, et al. Production and first-inman use of T cells engineered to express a HSVTK-CD34 sort-suicide gene. PLoS One 2013;8:e77106.
65. Qasim W, Gilmour K, Zhan H, et al. Interferon-gamma capture T cell therapy for persistent adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol 2013;161:449-452.
66. Himoudi N, Morgenstern DA, Yan M, et al. Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 2012;188:1708-1716.
67. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 2007;7:325-334.